Alogliptin priced and set for its first launch, in Japan
This article was originally published in Scrip
Executive Summary
Takeda's DPP-4 inhibitor for diabetes, Nesina (alogliptin), has received a reimbursement price in Japan, paving the way for what will be its first launch worldwide.